XTX202 in Patients With Advanced Solid Tumors
Advanced Solid Tumor
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 95 (final count)
- Started
- Jan 18, 2022
- Main results expected
- Mar 22, 2025
- Fully finished
- Mar 25, 2025
- Results posted
- May 28, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Incidence of Dose Limiting Toxicities (DLTs) (Phase 1 Part 1A Only)
Measured over: Cycle 1 day 1 up to just prior to the second dose of study drug at Cycle 2 day 1 (each cycle is 21 days)
Incidence of Treatment-emergent Adverse Events (Phase 1 Only)
Measured over: Up to 24 months
Investigator-assessed Objective Response Rate (ORR) Per RECIST 1.1 (Phase 2 Only)
Measured over: Up to 24 months
Incidence of Changes in Clinical Laboratory Values (Phase 1 Only) - Biochemistry
Measured over: Up to 24 months
Incidence of Changes in Clinical Laboratory Values (Phase 1 Only) - Hematology
Measured over: up to 24 months
Incidence of Changes in Clinical Laboratory Values (Phase 1 Only) - Thyroid Function
Measured over: Up to 24 months
Incidence of Changes in Clinical Laboratory Values (Phase 1 Only) - Coagulation
Measured over: Up to 24 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05052268 · record last updated 2026-05-28 · checked 2026-11-09 15:47 UTC